BEACOPP regimen

DRUG3 trials

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC, SWOG Cancer Research Network

Conditions

LymphomaNonneoplastic Condition

Phase 2

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

CompletedNCT00822120

SWOG Cancer Research NetworkLymphoma, Nonneoplastic Condition

Start: 2009-07-31End: 2022-06-30Updated: 2022-08-18

Phase 3

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Active, not recruitingNCT00005584

European Organisation for Research and Treatment of Cancer - EORTCLymphoma

Start: 1998-10-31Updated: 2025-08-05

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

CompletedNCT00049595

European Organisation for Research and Treatment of Cancer - EORTCLymphoma

Start: 2002-08-31Updated: 2025-08-05

Related Papers

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

Journal of Clinical Oncology2020-05-201 citations

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.

2019-10-0184 citations

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Blood2019-02-0647 citations

ABVD or BEACOPP<sub>baseline</sub> along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

2017-06-0824 citations